Bullish Case: Known: GH is ~$127 with backwardation and call volume dominating; GH IV surface shows a priced downside tail but comparatively flatter mid/near-ATM vols. Inferred: market expects idiosyncratic catalysts (Shield/Quest, reimbursement) to drive drift rather than macro. Calibration: my earlier 84–92 base-case looked too bearish as price rebounded to 127 post FDA/ACS digestion. Uncertain: CMS/coverage updates and Shield volume cadence.

Bearish Case: Known: GH IV surface remains steeply higher for deep puts than calls (downside convexity), while the return surface implies meaningful probability mass for modest negatives over shorter holding horizons. Inferred: despite SPY IV being lower/flatter, GH can fall on idiosyncratic/regulatory misses. Calibration: my “CMS delay” downside risk wasn’t fully realized yet, so it’s still an active tail. Uncertain: Shield ramp/coverage friction, competitor read-through, and near-term vol re-pricing into 6/18–7/17.

Potential Outcomes:

1. 30% Shield/Quest ramp validates and CMS stays permissive → +15–30%.
2. 25% Execution beat but gross-margin/cost pressure → +5–15%.
3. 20% CMS/coverage delay or competitor negative → -15–25%.
4. 10% Adverse trial/legal/partner slip → -25–40%.
5. 10% Macro risk-off (SPY drawdown >15%) → -10–20%.
6. 5% Buyout/strategic partnership headline → +30–60%.

Oracle watch (non-guarantee): if GH holds ~$120 into 6/18 while 120–125P IV stops rising vs calls, surface skew would be shifting toward upside drift.

June 04, 2026